News

GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...
Investors hate these 2 FTSE income stocks! Is this an opportunity?
Harvey Jones takes a look at 2 FTSE 100 income stocks that investors are snubbing right now to see whether there's a big ...
GSK's gepotidacin accepted for priority review by US FDA
(Alliance News) - GSK PLC on Monday said its gepotidacin drug has been accepted for priority review in the US as an oral option for the treatment of a form of sexually transmitted infection gonorrhoea ...
FTSE 100 today: Index, pound rise; data points to softening U.K. labour market
As of 0715 GMT, the blue-chip index FTSE 100 gained 0.3% and the British pound rose 0.09% against the dollar to above 1.34.
GSK gepotidacin edges closer to landmark approval for gonorrhoea
Drugmaker GSK moved closer to expanding its antibiotic portfolio on Monday, after US regulators accepted its application to review gepotidacin as a potential oral treatment for gonorrhoea.
Plus500 makes 'great progress' in H1, GSK's gepotidacin edges closer to FDA approval for gonorrhoea
OPEN The FTSE 100 was expected to open just 5.8 points higher ahead of the bell after wrapping up the previous session 0.6% lower at 9,095.73.
GSK: FDA to Review Gonorrhea Indication for Gepotidacin
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
LONDON BRIEFING: Plus500 announces buyback; Marshalls profit falls
(Alliance News) - Plus500 announced USD165.0 million of new shareholder returns, while Marshalls maintained its profit outlook, anticipating "no improvement in market activity levels" in the remainder ...
GSK's antibiotic gets FDA priority review for oral treatment of gonorrhoea
(Reuters) -British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for ...
U.S. Drug Regulator to Consider GSK's Gepotidacin as Gonorrhea Treatment
More than 600,000 cases of gonorrhoea were reported in the U.S. in 2023, according to the U.S. Centers for Disease Control and Prevention. There are no vaccine licenses in the U.S. for preventing the ...
GSK's antibiotic drug gepotidacin gets priority review by FDA
British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral ...
Becker's Hospital Review2d
GSK to receive $370M from patent settlement
GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...